Skip to site menu Skip to page content

Formulation Development and Compaction of Itraconazole Amorphous Solid Dispersions Tablets Using Quality by Design Principles

By MEDELPHARM

Itraconazole (ITZ), a BCS Class II drug exhibiting low solubility (1-4ng/mL in water) requires formulation enhancement to achieve enhanced bioavailability. To tackle this problem, amorphous solid dispersions (ASDs) of ITZ in a polymer matrix (Kollidon® VA64) were produced using the Hot Melt Extrusion (HME) process.

ASDs improve the poor solubility of the BCS Class II drug, compared to its pure crystalline form. However, this enhancement is impaired at the tabletting stage due to the high dose (100mg) requirement and the presence of high polymer content (70%).

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content